Six decisions of the EPO's Boards of Appeal use a string of cautionary tales to map the absolute floor of what patent applications for AI inventions must disclose — and ...
Continue reading
GPS spoofing, dual-use technology and the intellectual property question European developers must now ask
Continue reading
I am very honored to announce that I have had the opportunity to write a book in Japanese, which has been published. The b...
Continue reading
All articles
Maiwald advised Royalty Pharma on its acquisition of a portion of Neurimmune’s royalty interest in AstraZeneca’s investigational therapy cliramitug. The transaction is valued at up to USD 425 million, comprising an upfront payment of
Continue reading
Royalty Pharma and Denali have entered into a $275 million financing agreement which, pursuant to a synthetic royalty agreement, is based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali’s lead investigational TransportVehicle™-enabled enzyme rep...
Continue reading
Royalty Pharma has acquired a royalty interest in Amgen's Imdelltra, an innovative BiTE antibody for the treatment of small cell lung cancer, from BeOne Medicines for an upfront payment of $885 million. The agreement allows BeOne to sell additional royalty rights in Imdelltr...
Continue reading
Maiwald in the press
We are delighted to congratulate Iris Müller and Matthia...
Continue reading
Maiwald, one of Germany’s leading intellectual property law firms, has appointed Dr. Kerstin Wolff as Partner effective from 1 March 2026. This appointment further strengthe...
Continue reading
With retroactive effect from the beginning of the new year, Maiwald, one of Germany's leading intellectual property law firms, has appointed Martina Boidol, Dr. Anja Fux, and ...
Continue reading
All Staff News
The publication examines the Transferable Data Exclusivity Voucher (TDEV) as one of the most innovative elements of the proposed reform of European pharmaceutical legislation....
Continue reading
All publications
We are delighted that IAM has once again recognised several Maiwald partners in the Strategy 300: The World’s Leading IP Strategists 2026 list. ...
Continue reading
We are delighted that numerous Maiwald practitioners have once again been recognised by Managing IP (MIP) in its 2026 IP STARS rankings.
Continue reading
We are very delighted to announce that Maiwald has once again been recognised by Managing IP (MIP) as one of the leading intellectual property law firms in Germany in the
Continue reading
All awards
Tue.
15
On 15–16 September 2026, the Pharma & Biotech Patent Litigation at IP Litigation North America will take place at the Royal Sonesta Boston, bringing together U.S. life sciences IP leaders to develop and refine effective patent litigation strategies. The Pharma & Biotech Patent Litigation track is the premier platform for in‑house counsel, patent litigators and ...
Continue reading
Mon.
21
On 21–22 September 2026, the Munich IP Forum will once again bring together leading representatives from industry, private practice, the judiciary, and the patent profession in Munich. The event provides a platform for exchanging insights on the latest developments in European patent law, with a particular focus on the Unified Patent Cou...
Continue reading
Tue.
13
The BIOTECH SUMMIT AUSTRIA enters its next chapter: on 13–14 October 2026, the Austrian and international biotech community will meet in Innsbruck to discuss current developments, opportunities and challenges in the sector. The summit brings together leading figures from academia, industry, start‑ups, investment, policy and life‑science ecosystems – creating exactl...
Continue reading
Wed.
15
On 15 July 2026, the Tag der gewerblichen Schutzrechte will once again take place at the Liederhalle in Stuttgart. The event brings together experts from industry, academia and intellectual property practice to discuss current developments in patent, trade mark and innovation law. Maiwal...
Continue reading
All events